Verastem Oncology’s pipeline is focused on novel small molecule drugs that seek to treat cancer by inhibiting critical signaling pathways that promote cancer cell survival and tumor growth.
RAF/MEK and FAK
PI3K Delta Gamma
These studies are investigating treatments or outcomes that have not received approval from a Health Authority. There is no guarantee that the outcome of these studies will result in approval.
Investigator Sponsored Trials (IST)
The mission of Verastem Oncology Investigator Sponsored Trial (IST) program is to advance the medical and scientific knowledge pertaining to our product candidates and disease states of interest. We welcome collaboration with researchers and sponsoring institutions.
For additional details regarding our IST program or to submit a research request, please complete and submit the below form via email to verastem-IST@verastem.com.